



ten23 health obtains “Pending B Corp” status and joins both the “Swiss Triple Impact Directory” and the “United Nations Global Compact” (UN GC) program

- ten23 health, the human-centric and sustainable CDMO, has received the “Pending B Corp” status
- ten23 health has also concluded its journey with Swiss Triple Impact (STI) and is now listed in the STI Directory
- In addition, ten23 health has joined the United Nations (UN) Global Compact program

Basel, May 30th 2022 ten23 health®, a global contract development and manufacturing organization (CDMO) announced today it has achieved various milestones on its journey towards being a leading fair and sustainable pharmaceutical service provider.

As of today, ten23 health becomes a “**Pending B Corporation**”, which means that the company meets the legal accountability requirement for B Corp Certification and takes measures to manage its social and environmental performance. Pending B Corp status is valid for a non-renewable one-year term, after which ten23 health aims to obtain the full B Corp Certification. B Corp Certification is a designation that a business meets high standards of verified performance, accountability, and transparency on factors from employee benefits and charitable giving to supply chain practices and input materials. In order to achieve the full B Corp Certification, a company must demonstrate high social and environmental performance, integrate commitments to stakeholders into company governing documents and exhibit transparency on performances vs B Lab’s standards. More information about B Corp: www.bcorporation.net

In addition, ten23 health announced today that it has completed the “**Swiss Triple Impact (STI)**” program, following the three-step pathway for concrete commitments related to the UN Sustainable Development Goals (SDGs) and becomes a listed **STI Directory** member. The STI Directory is one of the largest listings of Swiss organizations to have taken bold and concrete commitments to contribute to the SDGs and the 2030 Agenda. More information about STI: www.swisstripleimpact.ch

ten23 health has also joined the “**United Nations Global Compact**” (UN GC) program, the world’s largest corporate sustainability initiative, aligning company strategies and operations with universal principles on human rights, labour, environment and anti-corruption and taking actions that advance societal goals. More information about UN Global Compact: Homepage | UN Global Compact

About ten23 health®

ten23 health®, located in Basel, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. Swissfillon, located in Visp, Switzerland, is a world leader in the sterile production of complex pharmaceutical dosage forms and a wholly-owned subsidiary of ten23 health. ten23 health combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called the Avogadro constant and equals $6.022 \cdot 10^{23}$. The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity, and Infrastructure, specializing in core investment markets in Northern Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies with an Enterprise Value typically between €100m - €500m. The company backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, industrial, healthcare and business and technology services industries.

Media contacts:

ten23 health: Mara Willa, mara.willa@ten23.health; +41 27 948 31 70

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com ; +44 20 7975 3021